Catherine Jacobson


Catherine identifies opportunities for clinical research partnerships that fulfill Tilray’s goal of advancing knowledge of cannabinoid science by partnering with physicians and medical institutions to generate data that will inform best treatment practices. Prior to joining Tilray, Catherine led a venture philanthropic fund addressing the lack of adequate drugs and devices to treat pediatric epilepsy. Before that, she served as a post-doctoral fellow at the University of California, San Francisco where she established GW Pharmaceuticals’ Expanded Access Investigational New Drug Application (IND) for Epidiolex for the treatment of children with severe medically refractory epilepsy.

Comments are closed.